A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: A multicenter study

Journal of Chemotherapy

Volumn 12, Issue 1, 2000, Pages 22-29

  Jessup, C ^a   Reyes, G ^a   Fothergill, A ^b   McCarthy, D ^b   Rinaldi, M ^b   Messer, S ^c   Pfaller, M ^c   Ghannoum, M ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Abelcet; AmBisome; Antifungals; In vitro susceptibility; Lipid based amphotericin B

Indexed keywords

AMPHOTERICIN B;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; FUNGUS CULTURE; FUNGUS GROWTH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; DRUG COMBINATIONS; FUNGI; HUMANS; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

EID: 0034105811     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40(2): 279-291.
2. Ghannoum MA. Future of antimycotic therapy. Dermatol Ther 1997; 3: 104-111.
3. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27(3): 603-618.
4. Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998; 36(10): 2817-2822.
5. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998; 42(6): 1412-1416.
6. Oakley KL, Moore CB, Denning DW. Comparison of In vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999; 43(5): 1264-1266.
7. Tollemar J, Ringden O. Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Safety 1995; 13(4): 207-218.